New Delhi: Home-grown COVID-19 vaccine Covaxin has shown to develop long-term antibody and T-cell memory responses 3 months after the shot in Phase-1 trials.
Bharat Biotech said the safety outcome in Phase-2 trial was found to be tolerable and it is expected that the antibodies produced will last for 6 to 12 months.
Memory T cells are antigen-specific T cells that stay in the body for a long term after an infection is eliminated. No serious adverse reaction was observed, the company said in a research paper.
Covaxin, now in Phase-3 trials, was tried on 380 healthy children and adults during the Phase-2 trials. As many as 13,000 volunteers have been recruited for Phase III trials and a total of 26,000 participants across multiple sites will be needed for the trials. AIIMS Delhi is recruiting more volunteers to join the trials.
Also Read: Vaccine To Fight New Coronavirus Strain Can Be Made In 6 Weeks If Required: BioNTech
New Delhi: The Supreme Court on Tuesday held that states are not empowered by the…
New Delhi: The central government has sent a notice to Wikipedia—which endorses itself as a…
Bhubaneswar: Four journalists from Odisha sustained critical injuries when as the SUV carrying them rammed…
Puri: Gajapati Maharaja Dibyasingha Deb on Tuesday said legal action would be initiated against International…
New Delhi: In a big relief to about 16,000-odd madrasas in Uttar Pradesh, the Supreme…
Bhubaneswar: A young man, stated to be a social worker, was critically injured after being…
Off with his head', orders the Queen of Hearts and off goes a head. The…
Ottawa: A Canadian cop, identified as Sergeant Harinder Sohi—a Peel Regional Police officer— was reportedly…